



Fig. S1. The MEK inhibitor, PD0325901 combined with erlotinib (A), afatinib (B) or pelitinib (C) synergistically decreases the survival of osimertinib-resistant cell lines The given cell lines plated in 96-well plates were exposed to the indicated concentrations of PD0325901 (PD901) alone, a tested EGFR-TKI alone or their respective combinations. After 3 days, cell numbers were estimated using the SRB assay. The data are means \pm SDs of four replicate determinations. The numbers inside the graphs are CIs for the given combinations.